- Home
- Automated
- List of product information
- NEULASTIM PRE-FILLED SYRINGE 6MG/0.6ML [SIN13200P]
NEULASTIM PRE-FILLED SYRINGE 6MG/0.6ML [SIN13200P]
Active ingredients: NEULASTIM PRE-FILLED SYRINGE 6MG/0.6ML
Last updated 26 October 2025
On this page
Product Info
NEULASTIM PRE-FILLED SYRINGE 6MG/0.6ML
[SIN13200P]
Product information
Active Ingredient and Strength | PEGFILGRASTIM - 6 MG/0.6 ML |
Dosage Form | INJECTION, SOLUTION |
Manufacturer and Country | AMGEN MANUFACTURING LIMITED LLC (AML OR AML LLC) - UNITED STATES |
Registration Number | SIN13200P |
Licence Holder | AMGEN BIOTECHNOLOGY SINGAPORE PTE LTD |
Forensic Classification | PRESCRIPTION ONLY MEDICINES |
Anatomical Therapeutic Chemical (ATC) code | L03AA13 |
2.1 Therapeutic Indication(s)
Reduction in the duration of neutropenia and the incidence of febrile neutropenia in patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes).
2.2 Dosage and Administration
Adults (≥ 18 years): One 6 mg dose (a single pre-filled syringe) of pegfilgrastim is recommended for each chemotherapy cycle, administered as a subcutaneous injection approximately 24 hours following cytotoxic chemotherapy.
Neulastim therapy should be initiated and supervised by physicians experienced in oncology and/or haematology.
2.3 Contraindications
Hypersensitivity to the active substance or to any of the excipients listed in section 1.5 – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.